[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351879-105":59,"doc-detail-351879-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-emerging-role-of-oncolytic-virotherapy-in-genitourinary-malignancies-review","The emerging role of oncolytic virotherapy in genitourinary malignancies - review","","Genitourinary cancers drive substantial global morbidity and mortality, with advanced disease often constrained by resistance to surgery, chemotherapy, radiotherapy, and immune checkpoint inhibitors. Tumor immune evasion and toxicities limit durable benefit, largely through the immunosuppressive tumor microenvironment and tumor adaptation to drugs. Oncolytic viruses have emerged as a promising viroimmunotherapy platform, combining direct oncolysis of tumor cells with systemic activation of anti-tumor immunity. This review analyzes key mechanistic foundations, viral platforms, clinical progress, and future directions including personalized strategies, CRISPR-based engineering, and biomarker-driven translation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-emerging-role-of-oncolytic-virotherapy-in-genitourinary-malignancies-review/351879/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-emerging-role-of-oncolytic-virotherapy-in-genitourinary-malignancies-review/351879.png","ImageObject",300,407,{"name":92,"@type":93},"Franzy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are current therapies often insufficient for genitourinary cancers?","Question",{"text":112,"@type":113},"Resistance to immunotherapy and chemotherapeutic agents, plus immunosuppressive tumor microenvironment effects, can limit durable responses. Tumor immune evasion and drug adaptation further sustain this therapeutic gap.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What dual mechanism makes oncolytic viruses promising for genitourinary oncology?",{"text":117,"@type":113},"Oncolytic viruses can directly lyse tumor cells and also stimulate robust systemic anti-tumor immune responses. This combination can help reprogram the immunosuppressive tumor microenvironment.",{"name":119,"@type":110,"acceptedAnswer":120},"What topics does the review cover about oncolytic virotherapy?",{"text":121,"@type":113},"It examines mechanistic underpinnings such as direct oncolysis and immunogenic cell death, modulation of the tumor microenvironment, and genetic engineering strategies. It also highlights viral platforms, landmark clinical advances, and future perspectives for personalized therapies, CRISPR-based engineering, and biomarker-driven translation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351879,1790507034,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336478945519,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","OPEN ACCESS  \nEDITED BY  \nErnesto Mejías-Pérez,  \nUniversity of Cordoba, Spain  \nREVIEWED BY  \nAlexandros G Georgakilas,  \nNational Technical University of Athens, Greece  \nGabri Van Der Pluijm,  \nLeiden University Medical Center (LUMC), Netherlands  \n*CORRESPONDENCE  \nLeonardo O. Reis,  \n [reisleo.l@gmail.com](reisleo.l@gmail.com)  \nRECEIVED 14 March 2026  \nREVISED 25 May 2026  \nACCEPTED 27 May 2026  \nPUBLISHED 15 June 2026  \nCITATION  \nBaboghlian J, Vohra J, Assoni L, Folguieri MS, Rocha GZ, Amorim JH, Shariat SF and Reis LO (2026) The emerging role of oncolytic virotherapy in genitourinary malignancies.  \nFront. Cell Dev. Biol. 14:1830852 .  \ndoi: 10.3389/fcell.2026.1830852  \nCOPYRIGHT  \n© 2026 Baboghlian, Vohra, Assoni, Folguieri, Rocha, Amorim, Shariat and Reis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nTYPE Review  \nPUBLISHED 15 June 2026  \nDOI 10.3389/fcell.2026.1830852  \nThe emerging role of oncolytic virotherapy in genitourinary malignancies  \nJuliana Baboghlian 1,2, Jasmine Vohra 3, Lucas Assoni 1,2, Marina S. Folguieri 1,2, Guilherme Z. Rocha 1,2,  \nJaime Henrique Amorim 2,4, Shahrokh F. Shariat 2,5,6,7,8,9,10,11,12 and Leonardo O. Reis 1,2,13*  \n1UroScience, School of Medical Sciences, University of Campinas (UNICAMP), São Paulo, Brazil, 2INCTUroGen, National Institute of Science, Technology and Innovation in Genitourinary Cancer, São Paulo, Brazil, 3Department of Biomedical Engineering, Vidyalankar Institute of Technology, Mumbai, Maharashtra, India, 4Western Bahia Virology Institute, Center of Biological Sciences and Health, Federal University of Western Bahia, Barreiras, Bahia, Brazil, 5Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria, 6Institute for Urology and Reproductive Health, I. M. Sechenov First Moscow State Medical University, Moscow, Russia, 7Department of Urology, Lazarski University, Warsaw, Poland, 8Department of Urology, Weill Cornell Medical College, New York, NY, United States, 9Department of Urology, University of Texas Southwestern, Dallas, TX, United States, 10College of Medical Health Technologies, Al-Turath University, Baghdad, Iraq, 11Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan, 12Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria, 13ImmunOncology, Pontifical Catholic University of Campinas (PUC-Campinas), São Paulo, Brazil  \nGenitourinary cancers represent a significant global health burden, accounting for millions of new cases annually and high mortality, particularly in advanced disease. Conventional therapies such as surgery, chemotherapy, radiotherapy, and immune checkpoint inhibitors have improved outcomes but are often limited by resistance, tumor immune evasion, and treatment-related toxicities. Oncolytic viruses, with their dual capacity to directly lyse tumor cells and stimulate systemic anti-tumor immunity, have emerged as a promising therapeutic platform in genitourinary oncology. This review provides a comprehensive analysis of the mechanistic underpinnings of oncolytic viruses’ therapy, encompassing direct oncolysis, immunogenic cell death, modulation of the tumor microenvironment, and genetic engineering strategies. We highlight key viral platforms, landmark clinical advances, and future perspectives in personalized therapies, CRISPRbased genetic engineering, and biomarker-driven clinical translation. Taken together, the integration of oncolytic viruses into genitourinary cancer management represents a rapidly maturing field, with the potential to transform curr","cbCaicViuUD4HQH0","https://ap.wps.com/l/cbCaicViuUD4HQH0","pdf",2897708,23,"English","# Introduction\n## Disease burden and treatment challenges\n## Rationale for oncolytic virotherapy","[{\"question\":\"Why are current therapies often insufficient for genitourinary cancers?\",\"answer\":\"Resistance to immunotherapy and chemotherapeutic agents, plus immunosuppressive tumor microenvironment effects, can limit durable responses. Tumor immune evasion and drug adaptation further sustain this therapeutic gap.\"},{\"question\":\"What dual mechanism makes oncolytic viruses promising for genitourinary oncology?\",\"answer\":\"Oncolytic viruses can directly lyse tumor cells and also stimulate robust systemic anti-tumor immune responses. This combination can help reprogram the immunosuppressive tumor microenvironment.\"},{\"question\":\"What topics does the review cover about oncolytic virotherapy?\",\"answer\":\"It examines mechanistic underpinnings such as direct oncolysis and immunogenic cell death, modulation of the tumor microenvironment, and genetic engineering strategies. It also highlights viral platforms, landmark clinical advances, and future perspectives for personalized therapies, CRISPR-based engineering, and biomarker-driven translation.\"}]","The emerging role of oncolytic virotherapy in genitourinary malignancies - review | PDF",1790096377,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d19912a79ed2135a23b8bae773bd91c7.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/47922d0aee184d87203c397af310b2bf.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f93002e70186916795bc7bbe2652eb2.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/76b7dcbf1d3be0ea0a431999d0b410ca.webp",980,1385]